Immunotherapy Raises Survival for Sarcomatoid Mesothelioma Patients – Mesothelioma Guide

1.888.385.2024
Get the complete guide to fighting mesothelioma. In our free guide you will learn about:
Sign up for our free Doctor Match program and we will:
Many patients have improved their prognosis and even beat their mesothelioma through clinical trials.
Clinical trials can provide:
Jodi has been a survivor of pleural mesothelioma for over multiple decades.
Paul has been a survivor of peritoneal mesothelioma for more than two decades.
Our Veterans Support Guide explains:
There is over $30 billion in financial assistance available for mesothelioma patients.
By: Devin Golden
May 13, 2022
By: Devin Golden
May 12, 2022
By: Devin Golden on October 26, 2021
Sarcomatoid mesothelioma is the toughest cell histology for this cancer. Most surgeons won’t operate on these cases, and chemotherapy does little to slow tumor growth.
For these patients with few options, immunotherapy is their best option.
A study out of Germany showed how immunotherapy adds months of survival to cases of sarcomatoid mesothelioma. The improvement in outcome is far less for the other cell type: epithelioid mesothelioma. One mesothelioma specialist in the United States affirms his belief in immunotherapy as a first‑line treatment for rare sarcomatoid cases.
The German Institute for Quality and Efficiency in Health Care provided immunotherapy to all cases of malignant mesothelioma. Most people had epithelioid histology, while around 20% had a sarcomatoid diagnosis.
The study gave patients Opdivo and Yervoy, two immunotherapy drugs for mesothelioma. Opdivo and Yervoy are approved, as a substitute for chemotherapy, for unresectable cases. These two immune checkpoint inhibitors target specific protein receptors on cancer cells and T‑cells. Blocking the receptors allows T‑cells to target mesothelioma cells more effectively.
Epithelioid patients survived on average 19 months with immunotherapy, compared to just 16 months with mesothelioma chemotherapy. For sarcomatoid cases, the difference was larger:
“For patients with non‑epithelioid tumour histology, there is an indication of considerable added benefit,” the researchers wrote. “An added benefit of nivolumab plus ipilimumab compared to a combination of pemetrexed and platinum‑containing chemotherapy is not proven for patients with epithelioid tumour histology.”
Dr. Wickii Vigneswaran is the Director of Thoracic Surgery at Loyola University Health System. He said the hospital’s protocol is to recommend immunotherapy as a first‑line therapy for sarcomatoid mesothelioma. For epithelioid cases, he said the approach is chemotherapy and then hopefully surgery.
He’s not the only doctor believing in histology affecting therapy. A report in the JTO Clinical and Research Reports states non‑epithelioid cases are three times more likely than epithelioid cases to receive immune checkpoint inhibitors.
Sources & Author

Devin Golden is the content writer for Mesothelioma Guide. He produces mesothelioma-related content on various mediums, including the Mesothelioma Guide website and social media channels. Devin’s objective is to translate complex information regarding mesothelioma into informative, easily absorbable content to help patients and their loved ones.

Read More

Want to learn more?
Get in depth knowledge about your diagnosis & the best treatments.
Mesothelioma News in Your Inbox
We’ll deliver the information you need directly to your email.
Proton Radiation Therapy Growing in Popularity for Mesothelioma and Lung Cancer
by Devin Golden
May 13, 2022
COVID Vaccines Work During Cancer Treatment
by Devin Golden
May 12, 2022
Ban of Menthol Cigarettes Should Reduce Lung Cancer Cases
by Devin Golden
May 4, 2022
Intraoperative Chemotherapy With Mesothelioma Surgery Results in Longer Life
by Camryn Keeble
April 26, 2022
Sources & Author
Devin Golden is the content writer for Mesothelioma Guide. He produces mesothelioma-related content on various mediums, including the Mesothelioma Guide website and social media channels. Devin’s objective is to translate complex information regarding mesothelioma into informative, easily absorbable content to help patients and their loved ones.
Mesothelioma Guide · © 2022 · All Rights Reserved · Privacy Policy · Disclaimer
The information provided by MesotheliomaGuide.com is not a substitute for professional medical advice.
Thank you!

Our mission is to guide mesothelioma patients and their loved ones toward answers, care options, and free health solutions that improve their lives. Learn More
We strive to provide the best service to patients with mesothelioma and their loved ones. We value your privacy and will never sell or rent your personal information.
This site complies with the HONcode standard for trustworthy health information: verify here.
Mesothelioma Guide · © 2022 · All Rights Reserved
Privacy Policy · Disclaimer
The information provided by MesotheliomaGuide.com is not a substitute for professional medical advice.

source

Related posts

Leave a Reply

Your email address will not be published.